Utilising Hull Lung Health Study Data to Investigate the Performance of TidalSense Diagnostic Algorithms to Identify COPD and Pre-COPD Among Participants in the FRONTIER Programme.
Launched by CHIESI UK · Jan 16, 2025
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well a new tool called TidalSense can help diagnose Chronic Obstructive Pulmonary Disease (COPD) and identify early signs of the disease, known as pre-COPD. COPD is a lung condition that makes it hard to breathe, and pre-COPD means a person has symptoms or changes in their lungs but does not yet have significant airflow problems. The study will compare TidalSense to standard lung tests to see if it can accurately identify people with COPD and those at risk of developing it within a year. Additionally, researchers will analyze blood samples from participants to see if certain biomarkers (substances in the blood) can help with early diagnosis.
To participate in this study, you need to be part of the Hull Lung Health Study and have symptoms like breathlessness or a cough, or evidence of emphysema from a lung scan. This trial is open to adults aged 55 to 75 who have ever smoked and are registered with a Hull GP. If you join, you’ll undergo tests and possibly provide blood samples to help researchers learn more about COPD. The trial is not yet recruiting participants, but if you meet the criteria, you could play an important role in improving how we diagnose and understand this condition.
Gender
ALL
Eligibility criteria
- • All Hull Lung Health Study participants that attend a one-stop diagnostic clinic appointment as part of the FRONTIER Programme (NHS Lung Health Check) will be eligible for inclusion in this study.
- • Prospective consent provided for use of data for research purposes and for future contact as part of the Hull Lung Health Study
- Inclusion criteria:
- * Participants in the Hull Lung Health Check Programme (ever smokers aged 55-75 and registered with a Hull GP) with one or more of the following symptoms during their lung health check:
- • Breathlessness
- • Cough
- • Bronchitis
- • Recurrent infections
- • AND/OR evidence of Emphysema on Low Dose CT
- Exclusion criteria:
- • -Existing COPD diagnosis noted at the time of their Lung Health Check or new COPD diagnosis since Lung Health Check attendance AND prescribed appropriate COPD therapy.
About Chiesi Uk
Chiesi UK is a leading pharmaceutical company dedicated to developing innovative healthcare solutions that enhance the quality of life for patients. As a subsidiary of the Chiesi Group, an international organization with a strong focus on research and development, Chiesi UK specializes in respiratory, neonatology, and rare disease therapies. The company is committed to advancing clinical research and fostering collaboration with healthcare professionals to bring effective treatments to market. With a robust pipeline and a patient-centered approach, Chiesi UK aims to address unmet medical needs and improve health outcomes in diverse therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Micheal Crooks, Prof
Principal Investigator
Hull York Medical School
Karen Watkins
Study Chair
Hull University Teaching Hospitals NHS Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported